Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Change in Account Payables (2017 - 2025)

Historic Change in Account Payables for Cue Biopharma (CUE) over the last 9 years, with Q3 2025 value amounting to -$1.3 million.

  • Cue Biopharma's Change in Account Payables fell 14986.37% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 million, marking a year-over-year decrease of 20333.08%. This contributed to the annual value of -$678000.0 for FY2024, which is 18805.19% down from last year.
  • Cue Biopharma's Change in Account Payables amounted to -$1.3 million in Q3 2025, which was down 14986.37% from -$157000.0 recorded in Q2 2025.
  • Cue Biopharma's Change in Account Payables' 5-year high stood at $2.6 million during Q3 2024, with a 5-year trough of -$3.6 million in Q4 2024.
  • Moreover, its 5-year median value for Change in Account Payables was $124000.0 (2023), whereas its average is $11547.3.
  • Its Change in Account Payables has fluctuated over the past 5 years, first tumbled by 233076.92% in 2023, then surged by 197016.13% in 2024.
  • Quarter analysis of 5 years shows Cue Biopharma's Change in Account Payables stood at $120398.0 in 2021, then skyrocketed by 422.43% to $629000.0 in 2022, then surged by 62.32% to $1.0 million in 2023, then tumbled by 457.49% to -$3.6 million in 2024, then soared by 64.93% to -$1.3 million in 2025.
  • Its last three reported values are -$1.3 million in Q3 2025, -$157000.0 for Q2 2025, and $961000.0 during Q1 2025.